Key Developments For Rochester Medical Corp
Rochester Medical Corp (ROCM.O) (Consolidated Issue listed on NASDAQ Global Market)
Rochester Medical Corporation Launches StrataSI And StrataNF Next Generation Foley Catheters
Rochester Medical Corporation announced the introduction of its Strata brands of Foley catheters. The company's StrataSI catheter is all-silicone, while the StrataNF version includes a nitrofurazone anti-infective matrix within the silicone.
Rochester Medical Corporation Comments On Q2 2008 Sales Outlook
Rochester Medical Corporation announced that led by continued solid growth of Rochester Medical Branded Sales, it expects greater overall sales in the second quarter of 2008. According to Reuters Estimates, analysts are expecting the Company to report revenue of $9.6 million for the same period.
Rochester Medical Corporation Announces Clinical Study Results
Rochester Medical Corporation announced the publication of results from a significant clinical study which further demonstrates the effectiveness of the Company's Infection Control Technology. The newly released September issue of the 'Annals of Internal Medicine' presents results of a randomized, double-blind, controlled clinical trial involving 212 adult patients at Denmark's Copenhagen Trauma Center. The study concluded nitrofurazone-impregnated urinary catheters reduced the incidence of catheter-associated bacteriuria and funguria in adult trauma patients, reducing the need to change or prescribe new antimicrobial therapy.
Rochester Medical Corporation Announces Settlement With Novation, L.L.C; Also Announces Contract
Rochester Medical Corporation announced that Novation, L.L.C. and the Company have reached a settlement Agreement under which the Company will dismiss Novation from the litigation which Rochester Medical filed on March 16, 2004 against C.R. Bard, Inc.; TYCO International (US) Inc.; Novation, L.L.C.; and Premier Purchasing Partners, L.P. Under the Agreement, Novation is awarding the Company a Technology Contract for its urological catheter products and related accessories, including the Company's Infection Control catheters and the Company is dismissing Novation from the litigation with prejudice. The Company has previously announced settlements with other defendants in the case, and litigation continues against the remaining defendant TYCO. The case is now scheduled for trial in February 2008.
Rochester Medical Corporation Announces Settlement Agreement With C.R. Bard, Inc.
Rochester Medical Corporation announced that C.R. Bard, Inc. and the Company have reached a Settlement Agreement under which the Company will dismiss C.R. Bard, Inc. from litigation which Rochester Medical filed on March 16, 2004 against C.R. Bard, Inc.; TYCO International (US) Inc.; TYCO Healthcare Group, L.P.; Novation, LLC; VHA Inc.; and Premier Purchasing Partners L.P. (Premier). Under the Settlement Agreement, Rochester Medical, represented by The Lanier Law Firm P.C. and Patton, Tidwell, & Schroeder, L.L.P., is dismissing C.R. Bard, Inc. from the litigation with prejudice, and C.R. Bard, Inc. is paying Rochester Medical a total of $49,000,000 out of which Rochester Medical will pay its attorney's fees.
